Empliciti Triple Combo Delays Disease Progression in Advanced Myeloma Patients, Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Trial of Virus Combo to Treat Multiple Myeloma Adding Keytruda to Mix for Patient Group
A Phase 1b trial testing a combination of Reolysin…
Mutations in Noncoding Regions of Human Genome Also Cause Cancer, Study Shows
While the best described cancer mutations are in regions…
Advanced Myeloma Patients Responding to Selinexor Plus Standard Therapies in Trial, Data Show
Updated clinical trial data show that selinexor added to…
Trillium Doses First Patient with TTI-622, a Candidate for Treating Myeloma, Lymphoma
Trillium Therapeutics recently dosed the first patient in its…
Companies Collaborating to Use ClonoSEQ Assay in Multiple Myeloma Trials Testing Isatuximab
Adaptive Biotechnologies is collaborating with Sanofi to use its…
